S. Yap et al., The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine beta-synthase deficiency, J INH MET D, 24(4), 2001, pp. 437-447
The pathological sequelae of untreated homocystinuria due to cystathionine
beta -synthase deficiency include ectopia lentis, osteoporosis, thromboembo
lic events and mental retardation. They occur at a significantly higher rat
e with poorer mental capabilities (mean IQ = 57) in the untreated pyridoxin
e-nonresponsive individuals. The mental capabilities of 23 pyridoxine-nonre
sponsive individuals with 339 patient-years of treatment were assessed usin
g age-appropriate psychometric tests and were compared to those of 10 unaff
ected siblings (controls). Of the 23 individuals, 19 were diagnosed through
newborn screening with early treatment, two were late-detected and two wer
e untreated at the time of assessment. Thirteen of the newborn, screened gr
oup who were compliant with treatment had no complications, while the remai
ning 6, who had poor compliance, developed complications. Good compliance w
as defined by a lifetime plasma free homocystine median < 11 <mu>mol/L. The
newborn screened, good compliance group (n = 13) with a mean age of 14.4 y
ears (range 4.4-24.9) had mean full-scale IQ (FIQ) of 105.8 (range 84-120),
while the poorly compliant group (n = 6) with a mean age of 19.9 years (ra
nge 13.8-25.5) had a mean FIQ of 80.8 (range 40-103). The control group (n
= 10) with mean age of 19.4 years (range 9.7-32.9) years had a mean FIQ of
102 (range 76-116). The two late-detected patients aged 18.9 and 18.8 years
had FIQ of 80 and 102, while the two untreated patients aged 22.4 and 11.7
years had FIQ of 52 and 53, respectively. There was no statistical evidenc
e of significant differences between the compliant, early-treated individua
ls and their unaffected siblings (controls) except for the FIQ, which was s
ignificantly higher than that of the unaffected siblings (p = 0.0397). Thes
e data, despite the relatively small numbers, suggest that early treatment
with good biochemical control (lifetime plasma free homocystine median < 11
<mu>mol/L) seems to prevent mental retardation.